The enhancement was significantly lower in GH secreting pituitary neuroendocrine tumor than in non-secreting ones. ¹⁾.

T2 weighted image differentiates GH secreting pituitary neuroendocrine tumors into subgroups with particular behaviors. This raises the question of whether T2-weighted signal could represent a factor in the classification of acromegaly in future studies ²⁾.

In patients with acromegaly, T2 weighted image signal intensity at diagnosis correlates with histological features and predicts biochemical outcome of first-line somatostatin analogues (SA) treatment ³⁾.

Each of the biomarkers, Ki-67 and p53, along with patient's age and mixed GH-prolactin secretion showed a kind of correlation with each of aspects of the clinical, hormonal and radiologic outcome of GH-secreting pituitary neuroendocrine tumors ⁴⁾.

D1-rGH could be a highly specific test for the early diagnosis of long-term acromegaly persistence, which is predicted by a value > 2.5 ng/mL with a great degree of certainty. The diagnostic performance of D2-rGH was insufficient. Further research is required to validate these preliminary results prior to modifying the postoperative management of acromegaly ⁵⁾.